Rapport Therapeutics (RAPP) Director Paul Buys $974K of Stock

Rapport Therapeutics, Inc. (NasdaqGM: RAPP) director Steven M Paul purchased 35,714 shares of the company on October 22, 2026. According to a Form 4 filing with the SEC, the shares were acquired at a price of $27.28 apiece for a total transaction value of about $974,277.

RAPP Rapport Therapeutics, Inc.

$26.53 ▼ -5.62% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Inside Steven M Paul's Rapport Therapeutics Trade

The open-market purchase substantially expanded the director's personal investment in the clinical-stage biopharmaceutical firm. Following the transaction, Steven M Paul held 77,380 shares of Rapport Therapeutics. This addition marked an 85.7% increase in his direct share ownership from a prior level of 41,666 shares.

Other Institutional Activity in Rapport Therapeutics

Trv Gp V, LLC reduced its holdings by 854,814 shares, ending with 6,280,525 shares worth about $166.6 million. Arch Venture Management, Llc kept its stake steady at 3,728,738 shares valued at roughly $98.9 million. Capital International Investors trimmed its position by 175,962 shares to finish with 2,921,958 shares worth about $77.5 million. Cormorant Asset Management, LP lowered its holdings by 299,881 shares, leaving it with 2,657,521 shares valued at about $70.5 million. Sofinnova Investments, Inc. maintained its position at 1,904,408 shares worth roughly $50.5 million.

Rapport Therapeutics, Inc. Stock Up 5.9%

Rapport Therapeutics shares closed at $26.53 on October 22, 2026. The stock recently traded around $26.53 as of October 22, 2026, sitting below its 50-day moving average of $39.90 and below its 200-day moving average of $35.75.

Recent Earnings

The company reported trailing twelve-month revenue of $20.0 million alongside a basic earnings per share of -$3.03. Its return on equity stood at -40.0%, and the next corporate earnings update is scheduled for November 5, 2026.

Dividend

Rapport Therapeutics does not pay a dividend to shareholders.

Insider Buying and Selling at Rapport Therapeutics, Inc.

Chief Operating Officer Cheryl Gault sold 10,000 shares on September 30, 2026, valued at $331,856. Chief Executive Officer Abraham N Ceesay disposed of 4,522 shares on October 7, 2026, totaling $143,273. Chief Financial Officer Troy A. Ignelzi bought 5,500 shares on October 21, 2026, at $26.10 per share for a total of $143,550.

Analysts Set New Price Targets

HC Wainwright & Co. reiterated its buy rating with a $66.00 price target on October 20, 2026. BTIG maintained a buy rating while raising its target from $75.00 to $89.00 on October 20, 2026. Jones Trading maintained a buy rating and lifted its target from $50.00 to $82.00 on October 21, 2026. Wells Fargo kept an overweight rating with a target of $50.00 on October 21, 2026, and Guggenheim maintained a buy rating while raising its target to $70.00 from $65.00 on October 21, 2026. Overall, analysts maintain a strong buy consensus with a mean target price of $69.46 across 15 opinions.

About Rapport Therapeutics

Rapport Therapeutics is a clinical-stage biotechnology enterprise based in Boston, Massachusetts. The company focuses on discovering and developing small molecule medicines aimed at treating central nervous system disorders. With 84 employees, it works to advance targeted therapies through clinical trials.

Bottom Line

Director Steven M Paul's purchase highlights notable insider activity ahead of the company's upcoming earnings report on November 5, 2026. Investors will likely monitor subsequent SEC filings and clinical updates to gauge corporate progress.